Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Carbapenems And Other Agents That Provide Broad-Spectrum Activity Are Preferred By Surveyed Physicians For The Treatment Of Intra-Abdominal Infections
Arlington Medical Res (AMR) and Decision Res find that surveyed physicians will increase prescribing of Wyeth"s Tygacil, Merck"s Invanz and Johnson & Johnson"s Doribax in the next five years for the treatment of intra-abdominal infections because of their potent broad-spectrum activity and efficacy against gram-negative and anaerobic organisms.

Researchers Identify New Function For Protein Missing In Duchenne Muscular Dystrophy
Researchers at the University of Minnesota and National Institutes of Health have identified a new function for the protein missing in people with the most common and ultimately lethal form of childhood muscular dystrophy.
News of the day
ARIAD Announces Preliminary Results From Ongoing Clinical Trial Of Its Investigational, Bcr-Abl Inhibitor In Drug-Resistant Chronic Myeloid Leukemia
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced preliminary clinical data from an ongoing Phase 1 clinical trial of its investigational, multi-targeted kinase inhibitor, AP24534, in patients with advanced hematological cancers. The study results provide initial clinical evidence of hematologic, cytogenetic and molecular anti-cancer activity of AP24534 in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML), including those with the T315I mutant variant of the target protein, Bcr-Abl. An abstract describing these data is being submitted for presentation at a major hematology meeting to be held later this year.
Sexual Health

Baxter Announces Findings From Premix Heparin IV Bag Investigation Related To Beebe Medical Center Adverse Event Reports

Today, Baxter is announcing that its investigation of reports from Beebe Medical Center has determined that the three patient events are unrelated to product quality involving the company"s heparin premix products. The company and the U.S. Food and Drug Administration (FDA) launched comprehensive investigations after being contacted on Friday, May 8, 2009 by Beebe Medical Center in Lewes, DE regarding adverse events involving three patients who experienced intracranial bleeding, a serious and life-threatening issue. Baxter worked with the hospital and FDA to rapidly collect information to assess the patient events and the hospital"s use of the company"s premix product. "Following extensive product testing and further medical evaluation, we are confident that the events at Beebe Medical Center are unfortunate, isolated, institution-specific issues, unrelated to the quality of Baxter"s heparin premix product," said Camille Farhat, general manager of Baxter Pharmaceuticals & Technologies, part of Baxter"s Medication Delivery business. "Our thoughts are with the patients and families involved in these tragic events." Baxter"s investigation included conducting an array of forensic and analytical tests to verify the product"s integrity, such as purity and potency testing, and to confirm that contaminants were not present. The supply chain, including raw materials, was examined and found to meet all requirements. All tests on samples obtained from the hospital, retained samples from the same lot, and samples produced before and after the lot in question confirmed that the product"s formulation was within specifications and met all requirements. Baxter"s medical investigation involved flying a team of physicians, pharmacists and nurses to Beebe Medical Center within 24 hours of notification to gather information about the sequence of events, patient conditions, other drugs and medical devices in use at the time, and to request additional medical information necessary to understand how three patients presented with intracranial bleeding. Evaluation of the medical information received indicated that the product performed as expected and that the intracranial bleeding was related to underlying medical conditions and risk factors that increase the relative risks involved in using a particular drug. Based on the findings from Baxter"s investigation, the company is confirming that the unfortunate patient events which occurred at Beebe Medical Center were isolated, institution-specific issues and this critical product continues to be safe and effective to use. Baxter International


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009